High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma

High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma

Abstract Infection has emerged as the chief cause of non‐relapse mortality (NRM) post CD19‐targeting chimeric antigen receptor T‐cell therapy (CAR‐T) therapy. Even though up to 50% of patients may remain infection‐free, many suffer multiple severe, life‐threatening, or fatal infectious events. The p...

Full description

Bibliographic Details
Main Authors: Maeve A. O'Reilly, Lorna Neill, Simon M. Collin, Neil Stone, Deborah Springell, Jeremy Mensah, Kathleen P. L. Cheok, Katarzyna Jalowiec, Reuben Benjamin, Andrea Kuhnl, Claire Roddie, Robin Sanderson
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:HemaSphere
Online Access:https://doi.org/10.1002/hem3.29

Internet

https://doi.org/10.1002/hem3.29

Similar Items